Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 1, 2007 Brian Lawler	Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note.
The Motley Fool June 2, 2005 Brian Gorman	Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye.
The Motley Fool August 8, 2007 Ryan Fuhrmann	Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth.
The Motley Fool May 13, 2005 Brian Gorman	Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude.
The Motley Fool November 11, 2004 Brian Gorman	Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
BusinessWeek May 31, 2004 Robert Barker	Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs.
The Motley Fool August 10, 2006 Stephen D. Simpson	Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note.
The Motley Fool March 1, 2006 Brian Gorman	Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note.
The Motley Fool May 25, 2006	When Debt Is Good Mortgage good, credit card debt bad. Investors, it's similar with companies. If a sizable chunk of income won't be eaten up by debt payment obligations, that means more flexibility and more opportunity. Still, you needn't balk at the first sight of debt. Just evaluate it carefully.
The Motley Fool June 8, 2004	Enterprise Value Explained Don't neglect debt and cash when determining a company's price tag.
The Motley Fool May 3, 2006	Enterprise Value, Explained Enterprise value (EV) represents a company's economic value -- the minimum someone would have to pay to buy it outright. It's an important number to consider when you're valuing a stock.
The Motley Fool July 15, 2004	When Debt Is Good vs. Bad Debt on a company's balance sheet can have two sides. Companies that can grow without using debt or issuing extra stock are in a more powerful position than others. Still, you needn't balk at the first sight of debt. Just evaluate it carefully.
The Motley Fool May 9, 2006 Stephen D. Simpson	Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool January 20, 2011 Jeremy Phillips	Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares?
The Motley Fool November 9, 2006 Brian Lawler	Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note.
The Motley Fool October 27, 2005	Enterprise Value Explained The enterprise value reminds all investors, large and small, that debt is a cost to the business.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool December 27, 2005	Foolish Fundamentals: Enterprise Value Don't overlook debt and cash when you're valuing a stock.
The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool December 6, 2005	When Debt Is OK Is debt good or bad? The answer is that not all debt is alike -- and not all debt is bad. Along the same lines, as investors we shouldn't assume that any debt on a company's balance sheet is a bad thing.
IndustryWeek September 1, 2006 David Blanchard	Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it.
The Motley Fool February 17, 2004 Selena Maranjian	How to Reduce Your Debt There's hope -- you can be debt-free once again! Steps to becoming debt free.
The Motley Fool April 4, 2005 Bill Mann	Let's Talk About Debt, Baby Individual investors seem to fear companies with debt. There's a reason they call it "leverage," though.
The Motley Fool August 19, 2005 Selena Maranjian	Getting Dirty With Debt Be wary of debt collectors, and consider investing in them! Learn about the debt collection industry to protect yourself in case they go after you. As a bonus, consider the industry as an investment opportunity.
The Motley Fool December 15, 2010 Seth Jayson	Does This Mean Hospira Will Burn You? Investors should watch Hospira's top line carefully during the next quarter or two.
Finance & Development June 1, 2002 Catherine Pattillo	External Debt and Growth Reasonable levels of external debt that help finance productive investment may be expected to enhance growth, but beyond certain levels additional indebtedness may reduce growth. An IMF study estimates two critical turning points.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
Finance & Development June 1, 2005 Raghuram Rajan	Straight Talk Debt Relief and Growth In a number of developed countries, debt relief for low-income countries has become an important political issue. Here's how to craft an optimal debt relief proposal.
The Motley Fool July 8, 2010 Selena Maranjian	Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul.
The Motley Fool October 22, 2004 Selena Maranjian	Credit Cards Spur Suicides Massive debt is alarming, but there's hope. You can pay it off.
The Motley Fool March 4, 2004 Selena Maranjian	Living on Borrowed Dimes Our debt is sky-high, and things are probably going to get worse. American consumer debt has doubled in the past decade -- and odds are, it will continue to climb, due in part to rising interest rates. Debt is even responsible for many divorces, and it might prevent you from retiring on schedule. Don't let yourself get run over by it.
IndustryWeek June 1, 2007 Traci Purdum	500 Largest U.S. Manufacturers: Manufacturing Giants This group of manufacturing leaders is demonstrating how to stay competitive in a global economy.